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Abstract
Background: The Swiss health ministry launched a national quality program ‘QualiCCare’ in 2011 to improve health
care for patients with COPD.
The aim of this study is to determine whether participation in the COPD quality initiative (‘QualiCCare’) improves
adherence to recommended clinical processes and shows impact on patients’ COPD care and on the impact of
COPD on a person's life.
Methods: CAROL is a cluster-randomized controlled trial with randomization on the general practioner (GP) level.
Thirty GPs will be randomly assigned to equally sized intervention group or control group.
Each GP will approach consecutively and regardless of the reason for the current consultation, patients aged 45
years or older, with a smoking history of ≥ ten pack-years (PY). Patients with confirmed (by spirometric evaluation)
COPD will be included in the study. GPs in the intervention group will receive ‘QualiCCare’ education, which
addresses knowledge, decision-making and behavioural aspects as well as delivery of care according to COPD
quality indicators and evidence-based key elements. In the control group, no educational intervention will be
applied and COPD patients will be treated as usual. The study period is one year.
The primary outcome measure is an aggregated score of relevant clinical processes defining elements in the care
of patients with COPD: smoking cessation counseling, influenza vaccination, motivation for physical activity,
appropriate pharmacotherapy, patient education and collaborative care. Given a power of 90% and a significance
level alpha of 5%, 15 GPs recruiting eight patients each will be necessary in both study arms. With an assumed
dropout rate of 20%, 288 patients will need to be included.
Discussion: It is important to develop and implement interventions that add value to COPD care considering
quality and efficiency. Care pathways modifying the knowledge and behavior of physicians have the potential for
improving care by transferring knowledge to clinical practice.
Trial registration: ClinicalTrials.gov: NCT01921556
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Background
Chronic obstructive pulmonary disease (COPD), an ill-
ness with a prevalence of about 10% in the adult Swiss
population causes significant burden to patients and the
health care system [1-3]. COPD often remains undiag-
nosed, and if diagnosed, attention is mainly directed to-
wards pharmacologic treatment, in particular treatment
of exacerbations [4]. The course of illness and quality of
life of patients can be improved by pharmacological and
non-pharmacological interventions [5,6]. Besides appropri-
ate pharmacological treatment, smoking cessation, sustain-
ing physical activity, influenza vaccination and empowering
patients to recognize and self-manage exacerbations in an
early phase define high quality care of patients with COPD.
Recently, we reported on gaps in COPD management in
Swiss primary care with overuse of inhaled corticosteroids
in moderate COPD and too little emphasis on smoking ces-
sation counseling and patient education [7] (Figure 1). Such
deficiencies in health care delivery lead to increased mor-
bidity and excessive use of health care resources [8] and
disclose the need for quality improvement.
Studies in various countries have demonstrated that fea-
tures of successful COPD care programs are the appropri-
ate delivery of medication, planned regular consultations,
activation and education of the patients, adequate exacer-
bation management and collaborative, integrated disease
management [9-13]. The successful COPD programs used
more or less a framework known as the chronic care
model (CCM) [14] for developing and implementing ac-
tivities to improve primary care for patients with chronic
illnesses. The CCM combines delivery system redesign,
clinical information systems, decision support, and self-
management support within a practice, linked with health
care organization and community resources beyond the
practice. Successful implementation of CCM elements
provided evidence for improved COPD care [4,15]. An
important assumption of the CCM is that the effect of a
number of elements and organizational factors combined
is higher than their sum of effects.
In 2011, the Swiss health ministry launched the national
quality initiative ‘QualiCCare’ to improve the quality of
care for COPD patients. In relation to international data,
it focuses on adherence with COPD guideline recom-
mendations and on CCM based actions that emerged
to improve the course of COPD by prevention and reduc-
tion of exacerbations, and thereby also health care costs
[4-6,16,17]. These actions include a more proactive and
coordinated COPD team care to provide self-management
support, smoking cessation counseling, annual influenza
vaccination, motivation for physical activity and pul-
monary rehabilitation and appropriate pharmacologic
treatment considering severity, symptoms and risk of
exacerbations. The central aspect of the ‘QualiCCare’ pro-
gram is a multifaceted implementation approach. It aims
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not only to increase knowledge but also internal motiv-
ation and decision-making by offering stimuli, resources
and written instruments [18-21]. Further it categorizes
and delineates specific professional and organizational in-
terventions and comprises a short list of evidence-based
practice items into a primary care ‘COPD care bundle’
that should guide and support better performance. So far,
experience with care bundles for COPD only exists for
discharge in patients hospitalized with COPD exacerba-
tions [22].
In Switzerland, such a multifaceted COPD targeted
quality program has not yet been broadly implemented
and evaluated. The aim of the study is, therefore, to evalu-
ate the effect of the ‘QualiCCare’ COPD intervention on
COPD management in patients with diagnosed COPD in
primary care practices in the Canton of Zurich.
Hypotheses
The ‘QualiCCare’ intervention will improve adherence to
suggested ‘good care’ standards in COPD, namely: smok-
ing cessation counseling, influenza vaccination, appropri-
ate pharmacotherapy with less overuse of inhaled steroids
and correct inhalation technique, consideration of exacer-
bations, physical activity, pulmonary rehabilitation and
patient education, and care coordination. Improvement
in these processes is the first step towards improved clin-
ical outcome measures as health status, and therefore, we
also expect over time, a reduced impact of COPD on pa-
tients’ lives.
Methods/Design
We will conduct a cluster-randomized controlled trial
(randomization on GP level) with primary care physicians
in the Canton of Zurich in the years 2013 and 2014.
Recruitment and eligibility of primary care physicians
GPs are eligible for participation if they provide care in
the routine primary setting (single handed practices and
group practices) to unselected patients.
About 300 GPs in the area of Zurich and Winterthur
are invited to an information meeting by a formal letter
of the Institute of General Practice and Health Services
Research of the University of Zurich and the Depart-
ment of Health of the Canton of Zurich. In this informa-
tion meeting an overview of the study will be given. The
main focus of the first information meeting for all GPs is
to present the project and to motivate GPs to take part
in the study. Additionally, the project will be presented
in several quality circle meetings in doctors’ networks
(regions Zurich, Winterthur).
GPs who agree to participate will be randomized, strati-
fied by practice organization (single handed versus group
practices). All participating GPs/practice assistants will
receive instruction by a pneumologist and a spirometry
technician in performing a spirometry. Practices in the
intervention group get detailed information on evidence-
based COPD management and ‘QualiCCare’ training ses-
sions and instruments, designed to increase knowledge,
internal motivation and decision-making and to support
incorporation of evidence into their daily work (details
described in the intervention section).
The GPs of the control group apply ‘care as usual’ with-
out receiving the ‘QualiCCare’ training and implementa-
tion tools.
Patient recruitment
All GPs are asked to approach consecutively and regard-
less of the reason for the current consultation, patients
aged 45 years or older with a smoking history of ≥ ten
pack-years (PY) and to include patients with COPD di-
agnosed by spirometric evaluation.
To assure an appropriate spirometric evaluation, all
GPs will participate in a spirometric training by a pneu-
mologist and a spirometry technician before starting the
patient recruitment process and before randomization of
the GPs. The aim of this procedure is to diagnose COPD
or confirm the diagnosis of COPD by a current and cor-
rect spirometry in both arms of the study.
Patient inclusion criteria
1) Males and females ≥ 45 years of age and
2) Smoker or ex-smoker (with at least ten PY) and
3) Obstruction in spirometry FEV1/FVC < 0.7
Patient exclusion criteria
1. No obstruction in spirometry (FEV1/FVC ≥ 0.7) or
2. Patients with history of asthma or hay fever or
3. Other concomitant pulmonary disease or
4. Patients with malignancies of any other system and/
or other severe disease with an estimated life
expectancy of less than six months or
5. Insufficient German language skills or
6. Patients who contact the practice for emergencies
only or as a substitute practice
The flow chart of GP and patient recruitment of the
study is shown in Figure 2.
Clinical interventions/guideline adherence
With the ‘QualiCCare’ intervention, we reach out to im-
plement the recommended key clinical processes in
primary care for patients with diagnosed COPD namely:
smoking cessation counseling, yearly influence vaccination,
counseling to increase motivation for physical activity and
pulmonary rehabilitation, self-management education with
a written action plan to do the right thing at the right time
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in case of an exacerbation; appropriate pharmacologic
treatment for stable and exacerbated COPD, and pro-
active, collaborative COPD care.
Implementation program
Instruction of the GPs and practice assistants in the
intervention group
Physicians randomized into the intervention group get a
‘QualiCCare’ training workshop designed to educate
professionals on the guidelines, but also and particularly,
governing professional behavior by feedback, reminders
and pathways that help to change their attitudes and
care behavior [23-25]. Based on behavioral and learn-
ing theory [26], ‘QualiCCare’ intervention not only tries
to increase knowledge but also internal motivation and
decision- making by stimuli and resources and by written
instruments that guide evidence-based decision support.
The education sessions will actively involve GPs and
practice assistants with tasks and responsibilities and also,
by demonstrating them (by interactive teaching, case vi-
gnettes and role plays), ways on how evidence-based tasks
could be incorporated into their daily work.
Three instruments (A-C) have been developed based
on a review of international and national guidelines and
in collaboration with the Swiss Respiratory Society, Swiss
Societies of Internal and General Medicine and College
of Primary Care Medicine, with a specific focus on pri-
mary care circumstances and needs. These instruments
will be introduced to the intervention group as working
tools for daily practice to support decision-making and
adherence with recommended COPD care.
A. The Swiss COPD quintessence for primary care is a
clinical guideline for GPs which is consistent with
international guidelines for COPD [27] and the
newly published Swiss COPD guideline [6], but
more comprehensive and summarizing the key
elements of COPD management for Swiss primary
care [28].
B. The COPD pocket guide contains evidence-based
information, assessment tools (MRC, CAT, STS),
opinion sheets (early diagnosis, smoking cessation
advice), treatment algorithm and decision aids for
the key COPD elements: Confirm diagnosis,
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Figure 2 Study flow chart.
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Optimize symptoms, Prevent deterioration, and
Develop network and self-management support. The
pocket guide also contains addresses and links to
useful information as well as for specialist support,
pulmonary rehabilitation and community resources
offering, for example, smoking cessation and patient
education.
C. The Primary care COPD Care bundle is something
new for the primary care setting. So far, experience
for COPD only exists for discharge care bundles for
COPD patients hospitalized with acute
exacerbations. The implementation of a discharge
care bundle improved adherence with optimum
health care practice [22]. Our primary care COPD
care bundle comprises a short list of evidence-based
practice items to be implemented into primary care
for patients with COPD. It can function as a
reminder and as a checklist of all necessary activities
that can be ticked as performance control. It is
expected to function as a stimulus for increased
guideline adherence and internal motivation for
behavior change.
Bundle items selected for primary care are:
1. Identify COPD in a smoker or ex-smoker (with at
least ten PY) with symptoms (cough, sputum or
dyspnea).
2. If the patient is still a smoker, offer smoking
cessation assistance.
3. Motivate for physical activity and consider/refer for
pulmonary rehabilitation.
4. Motivate for influenza vaccination.
5. Offer appropriate pharmacologic treatment for
stable and exacerbated COPD.
6. Demonstrate and check correct use of inhalers.
7. Give written information about COPD including
Lunge Zürich self-management booklet and an
action plan.
8. Offer proactive follow-up and integrated services
(for example follow-up, feedback and scheduling and
‘navigation’ functions by the trained practice
assistant, arranging appointments, and connecting
patients to internal and external providers and
resources).
A specialized and experienced team of a pneumologist
and a respiratory physiotherapist and master trainer will
hold the ‘QualiCCare’ training workshop (half a day ses-
sion). The three dimensions knowledge, skills and behavior
in COPD management are addressed with consideration of
the COPD care bundle items.
A ‘QualiCCare’ refresher course will be held six months
after the first training workshop.
Outcomes
Primary outcome
Difference in ‘quality of care process’ (total increase
in performed measures/fulfilled indicators) after one year
between COPD patients in the intervention and control
group as reported by the patient (described below).
Secondary outcomes
a. Percentage of COPD patients with FEV1 < 60%
and/or ≥ two exacerbations who received
 advice to participate in pulmonary rehabilitation
 referral to pulmonary rehabilitation
 a written action plan for exacerbation
management
 proactive follow up and integrated services
(arrangement for follow up and referrals)
b. Quality of life (CAT)
c. Aggregate measure for ‘quality of care process’
reported by the GPs
Details on the purpose defined, aggregate outcome meas-
ure (primary outcome and secondary outcome b):
Every process indicator will get a rating of 1, when
performed (or done) and 0 when not performed. The
range of the primary outcome will be from 0 to a max-
imum of 9, the range of the secondary outcome - applicable
only for a subgroup of patients - will be 0 to a max-
imum of 13:
Indicators for the primary outcome:
1. Smoking cessation advice
2. Smoking cessation intervention
3. Influenza vaccination
4. Assessment of physical activity
5. Advice for physical activity
6. Assessment of exacerbation frequency
7. Appropriate pharmacological treatment: (no inhaled
corticosteroids in patients with FEV1 > 50%
and < two exacerbations/year)
8. Instruction in correct inhalation technique
9. Information and patient education: additional
indicators for the secondary outcome: COPD
patients with FEV1 < 50% or ≥ two exacerbations
10. A written action plan for exacerbation management
11. Advice to participate in pulmonary rehabilitation
12. Referral to pulmonary rehabilitation
13. Proactive follow-up and integrated services
Quality of life
We use the COPD Assessment Test (CAT). The CAT
provides clinicians and patients with a reliable measure
of overall COPD-related health status for the assessment
and long-term follow-up of individual patients. The CAT
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is a validated short and simple patient-completed ques-
tionnaire that has been developed for use in routine clin-
ical practice to measure the health status and grading the
impact of COPD on patients’ life. The CAT is available in
different languages (http://www.catestonline.org). It com-
promises eight simple questions, eight items on a scale
of 0 to 5 with a total scoring range of 0 to 40; CAT
score < 10 low impact, 10 to 20 medium impact and > 30
very high impact of COPD on a patient’s life [29].
Measures at baseline and follow up
Baseline
Patient demographics: gender, age, race/ethnicity, employ-
ment status, and family background.
Clinical characteristics: comorbidities (predefined selec-
tion of frequent comorbidities cardiovascular, diabetes type
II), BMI, smoking status, PYs smoking, respiratory symp-
toms cough, sputum, dyspnea and severity of dyspnea
(Medical research council MRC dyspnea scale), spirometry
(FEV1/FVC < 70%) and grade of severity (FEV1 > 80%
GOLD I mild COPD, FEV1 50 to 80% GOLD II moderate
COPD, FEV1 30 to 50% GOLD III severe COPD, FEV1 <
30% GOLD IV very severe COPD) according to GOLD
guidelines. Burden of COPD in daily life assessed with the
COPD assessment test (CAT). Current drug therapy, exac-
erbations and health care utilization in previous year due
to pulmonary problems, including hospital admissions and
emergency department attendances or unscheduled visits
are also assessed.
Follow-up
We use a data collection tool with clinical questionnaires
for patients and GPs (each with an allocated correspond-
ing code) to measure performance.
Data collection procedures
Patient questionnaire
The patients will receive detailed written information on
the aim of the study. After giving their written informed
consent they will receive a questionnaire (T0) assessing
gender, age, employment status, and family background,
the CAT, information on respiratory symptoms (cough,
sputum, dyspnea), and severity of dyspnea (Medical re-
search council MRC dyspnea scale), smoking status, mo-
tivation to quit, exacerbations and health care utilization
(including unscheduled visits, emergency department at-
tendances and hospital admissions due to pulmonary
problems). Patients are asked at T0 whether, in the pre-
vious year before study inclusion, they had received:
advice to quit smoking, assessment and advice for phys-
ical activity or advice/referral to pulmonary rehabilitation,
recommendation/application of influenza vaccination,
patient education with defining COPD and information
about the main causes, signs and symptoms, information
on medication and using inhalation devices with face-to-
face instruction and demonstration of inhalation tech-
nique, information on how to identify and manage an
aggravation of symptoms (exacerbation) and an action
plan for exacerbation management including medication
adjustment for exacerbation treatment. In addition patients
are asked whether they have received COPD support by
community resources (lung associations, support groups)
and other specialized health professionals. Patients are
asked the same questions one year after study inclusion
T1. They receive the questionnaires and stamped enve-
lopes with the postal address of the university and are
asked to return the questionnaire in the envelope to the
university at T0, and T1 after 12 months.
Patients will also be informed that neither the GP nor
the practice team has any possibility of obtaining know-
ledge of their answers.
GPs
The GP will maintain a record of the participants with an
allocated code for each patient. This code is also marked
on the questionnaires. The university only receives the pa-
tients’ codes and has no access to their names.
A questionnaire is filled out by the GPs with informa-
tion on the professional characteristics (gender, age,
specialty, work time) and of the organizational context,
such as single or group practice, regional structures and
available resources.
At T0, the GP gives information for each participat-
ing patient on demographics, clinical characteristics:
comorbidities, BMI, smoking status, PYs smoking, infor-
mation on respiratory symptoms cough, sputum, dyspnea
and severity of dyspnea (Medical Research Council MRC
dyspnea scale) spirometry (FEV1/FVC < 0.7) and grade
of severity according to GOLD guidelines FEV1 > 80%
GOLD I mild COPD, FEV1 50 to 80% GOLD II moderate
COPD, FEV1 30 to 50% GOLD III severe COPD, FEV1 <
30% GOLD IV very severe COPD), exacerbation fre-
quency and current (pulmonary) drug therapy.
After 12 months (T1), GPs are asked about smoking
cessation counseling activities, yearly influenza vaccination
and assessment of physical activity; if ‘yes’, how was phys-
ical activity assessed? Possibilities include anamnesis and
objective tests, for example, sit to stand test (STS), six-
minute walking test, and ergometer. Also asked about are
motivation for physical activity and referral to pulmonary
rehabilitation, assessment of exacerbation frequency and
health care utilization in previous year, including hospital
admissions, emergency department attendances and un-
scheduled visits. Whether patient education activities are
given, verbally and/or via patient booklet, with definition
of COPD and information about the main causes, signs
and symptoms of COPD is also inquired into, as is
whether information on medication and using inhalation
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devices, face-to-face instruction and demonstration of in-
halation technique is supplied. Additionally, whether in-
formation on how to identify and manage an aggravation
of symptoms (exacerbation) and whether an action plan
for exacerbation management, including a written medi-
cation adjustment for exacerbation treatment is sup-
plied, is asked about. GPs are also asked whether they
educate patients in the practice or refer them to an exter-
nal COPD program connecting COPD patients with spe-
cialized health professionals and community resources
(lung associations, support groups).
This procedure will be carried out to compare patients’
reported procedures with GPs’ self-reported performed
procedures and is assessed as secondary outcome measure.
The GP questionnaires are also marked with the patient’s
code and will be returned to the university in a stamped
envelope. GP measurements will take place at baseline
(pre-data collection) and after 12 months (post-data collec-
tion). Pre-data collection is estimated to last three months.
An independent research assistant of the university
will enter the data directly into the SPSS program (ver-
sion 18.0 or higher, SPSS, Chicago, IL, USA).
For an intermediate outcome, we will assess mediating
processes with a self-efficacy scale for professional
knowledge, skills and behaviour before and right after
the ‘QualiCCare’ workshop and after 12 months.
The process evaluation will also include outreach visits
and interviews, which have shown to be effective strategies
to support implementations in primary care. Therefore,
one outreach visit will be performed eight to twelve weeks
after the training workshop for GPs and practice assistants
in the intervention group. The aim of this outreach visit is
to assess if the structures in the practices are appropriate
to perform care according to the study protocol. Further-
more, the visit aims to reveal possible problems which
might have occurred, and to discuss and implement ap-
propriate solutions. Whether the instruments are used as
intended will also be checked. The outreach visit will be
performed by a study nurse of the study center.
Statistical analysis
Calculation of sample size
Based on available data from Switzerland [7,30], and a
recently performed cross-sectional survey of our study
group, we assume a mean of four regarding the number
of performed indicators (primary outcomes 1 to 9 as
mentioned above) and a SD of 2.3. We assume an in-
crease in the intervention group in the mean of per-
formed indicators of 1.5. Given a power of 90% and a
significance level alpha of 5%, as well as an intracluster
correlation coefficient (ICC) of 0.04, we will need eight pa-
tients per GP assuming participation of 30 GPs, resulting
in 240 patients. Assuming a dropout rate of at least 20%
(dropouts are possible on a GP level but also on a patient
level, therefore this rate is estimated to be about 20%), we
will need 288 patients.
Data analysis
A t-test will be used for independent group comparisons
in the primary outcome between control and intervention
group. Each quality indicator itself can also be regarded
as a binary outcome (performing a specific procedure
(yes/no)). To analyze these binary outcomes separately
logistic regression will be used to model the relationships
between the outcome and treatment group, age and gen-
der. Other potentially important covariates will be identi-
fied through exploratory analyses. The longitudinal aspect
of the data can be incorporated into the model in various
ways; we will utilize the generalized estimating equations
(GEE) approach [31].
For continuous outcomes such as quality of life (QoL)
instruments, repeated measures analysis of variance is
appropriate [32].
Fixed effect parameters will include treatment group, age,
gender, and other potentially important covariates. The pri-
mary data analysis will follow the intent-to-treat (ITT) ap-
proach where appropriate. This means that all available
data from all individuals will be analyzed according to treat-
ment group assignment, regardless of whether or not each
individual actually received the assigned treatment.
Timeframe of the study
The recruitment of the 30 GPs is planned over two
months between July and August 2013 (−T2).
Patient eligibility screening and patient inclusion is
projected within a period of three months (−T1). The
intervention courses will start subsequently.
Assessments will be made as described above, T0 base-
line assessments start from the inclusion; at baseline, data
regarding COPD management in the year before inclusion
will also be assessed retrospectively from the patient charts
and transferred anonymously to the study center.
Final measurements (T1) will be performed one year
after the ‘QualiCCare’ intervention.
Ethical principles
The study is conducted in accordance with medical pro-
fessional codex and the Helsinki Declaration as of 1996 as
well as Data Security Laws and according to good clinical
practice guidelines.
Study participation of patients is voluntary and can be
cancelled at any time without provision of reasons and
without negative consequences for their future medical
care.
Patient informed consent
Previous to study participation, patients receive written
and verbal information about the content and extent of
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the planned study from the GPs; for instance about po-
tential benefits and potential risks to their health. In case
of acceptance, they sign the informed consent form.
In case of study discontinuation, all material will be
destroyed or the patient will be asked if he/she accepts
that existing material can be analyzed in the study.
Vote of the Ethics Committee
The study protocol is approved by the Ethics Committee of
the Kanton Zurich (reference KEK-ZH_number 2013-0189).
Data security/disclosure of original documents
The patient names and all other confidential information
fall under medical confidentiality rules and are treated
according to appropriate Federal Data Security Laws.
The results of the patient questionnaires are not access-
ible to the GPs. Questionnaires are directly mailed to
the study center by the patient.
All study related data and documents are stored on a
protected central server of the University of Zurich.
Only direct members of the internal study team can ac-
cess the respective files.
Intermediate and final reports are stored in the office
of the Department of General Practice and Health Ser-
vices Research at the Zurich University Hospital (USZ).
Discussion (expected results)
Improving care for people with chronic diseases is one
of the big challenges in health care worldwide [17]. In
this era plagued by ever-tightening health care resources,
it is of utmost importance to identify and implement in-
terventions that are of added value to quality and effi-
ciency of care [14,33]. Efficient professional interventions
and care pathways, which detail essential steps in the care
of patients, have the potential for improving patient care
by reaching quality standards and decreasing unwarranted
practice variation. However, evaluation of their impact is
important. According to Lemmens et al. [34] improve-
ment of expertise, information and resources will affect
behavioral intention, which leads to professional behav-
ioral change and this should lead to improved health ef-
fects. We expect that the ‘QualiCCare’ intervention can be
implemented into primary care practices and will consti-
tute a path forward for better quality in COPD care. After
adjusting for age, gender, number of chronic conditions,
participating sites are expected to show significant im-
provement for several quality indicators, including smok-
ing cessation advice, influenza vaccination, appropriate
medical therapeutics, rehabilitation and self-management
education efforts and better proactive, collaborative care
compared to the ‘usual care’ group.
Professional support and improvement in these pro-
cesses is the first step towards improved clinical out-
come measures as quality of life and therefore, we also
expect a significant difference for our secondary out-
come QOL assessed by the patient.
In addition, we try to identify professional behavior
change mechanisms and gain insight into some imple-
mentation processes that could help to open the ‘black
box’ that frequently lies between input and outcome of
interventions.
The vision that emerges from our study is of organiza-
tions that aim to implement best practice and to im-
prove the value of care in COPD, one of the world’s
major chronic illnesses. This study is, therefore, of great
interest not only from the patient perspective but also
from a health care system perspective.
Trial status
Patient recruitment had not started at the time of first
submission in August 2013.
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